Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business
The model's full reasoning — Q4 2017 call → NO我们根据提供的财报电话会议记录来判断。问题问的是管理层是否描述了公司最近获得了某种许可、批准、资格、认证、上市或访问权,并且通过这个新打开的门已经开始了实际业务,而大部分潜力还在后面。 在记录中,我们寻找相关描述。例如,关于DaVita Medical Group的收购,但那是收购,不是获得许可。关于Banmedica,也是收购。关于West Virginia的Optum整合资格平台,那是新合同,但可能算作新业务。但问题特别强调“permission, approval, qualification, certification, listing, or access right”由外部权威授予,允许公司销售或服务。在记录中,有提到“West Virginia became the first state to engage Optum to integrate program eligibility across all state sponsored health benefit program”,这算是一个新合同,但可能不是许可。另外,有提到“PreCheck MyScript”推出,但那是产品发布。还有“Rally”等。 更关键的是,问题要求三个条件:1) 访问权是真实且最近获得的(在过去几个季度内),2) 第一批业务已经开始,3) 大部分潜力还在后面。 在记录中,管理层提到了一些新业务,但似乎没有明确说“我们获得了某个批准,然后开始有业务,但大部分还没来”。例如,关于OptumRx的客户,但那是现有业务。关于Medicare Advantage的增长,那是现有业务。 也许关于“Nexus ACO”产品,但那是新产品,不是许可。 再仔细看,有提到“We expect to add Banmedica in the first quarter 2018”,但那是收购,不是许可。 或许关于“The healthcare transformation alliance relationship is off to an excellent start with 10 companies selecting OptumRx”,但那是客户选择,不是许可。 问题强调“outside authority, customer, partner, or institution”授予的访问权。在记录中,有提到“West Virginia became the first state to engage Optum to integrate program eligibility”,这算是一个州政府授予的合同,但那是合同,不是许可。而且,这个合同是新的,但业务是否已经开始?记录说“over half the state population or about 900,000 people will access Medicaid as well as other human surface benefits through Optum’s new integrated eligibility platform”,但这是未来时态,可能还没开始。 另外,有提到“we now manage more than $65 billion in annual billings on behalf of our diverse revenue management customers”,但那是现有业务。 也许关于“PreCheck MyScript”已经推出,但那是产品,不是许可。 再考虑“DaVita Medical Group”收购,但那是收购,不是许可。 或许关于“The Advisory Board”收购,也是收购。 所以,似乎没有明确描述“获得许可”的事件。 在电话会议中,管理层提到了“we expect to add Banmedica in the first quarter 2018”,但那是预期,不是已经获得。 另外,有提到“we are pursuing growth and diversification in five key areas”,但那是战略。 因此,我认为没有符合条件的事件。 所以答案应该是NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| NVAX | Novavax, Inc. | Q3 2023 | 2023-11-09 | F |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| BMY | Bristol-Myers Squibb Company | Q4 2016 | 2017-01-26 | F |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.